Envelope glycoproteins of varicella zoster virus (VZV) contain mannose 6-phosphate (Man6P) residues.
0.16-0.26 ,ug/ml) but not by chondroitin sulfate. Both heparin and Man6P are protective only when present about the time of inoculation. Heparin but not Man6P interferes with the attachment of VZV to cell surfaces; moreover, VZV binds to heparin-affinity columns. These data are compatible with a working hypothesis, whereby VZV attaches to cell surfaces by binding to a heparan sulfate proteoglycan. This binding stabilizes VZV, making possible a low-affinity interaction with another Man6P-dependent receptor, which is necessary for viral entry.
Varicella zoster virus (VZV) is an a-herpesvirus that causes varicella and zoster (1). Although VZV is extremely contagious in vivo, relatively little is known about its entry into target cells. Previous studies have revealed that oligosaccharides derived from glycoproteins of the VZV envelope contain mannose 6-phosphate (Man6P; ref. 2); moreover, Man6P and other phosphorylated monosaccharides protect cells from the cytopathic effect (CPE) of VZV with an order of potency that parallels their affinity for binding to the cationindependent Man6P receptor (MPRCi) . Treatment of cells with chloroquine, which reduces the expression of MPRCi at cell surfaces, also protects against infection by VZV. Electron microscopic immunocytochemical observations, furthermore, have revealed that enveloped virions are associated with MPRCi at the cell surface and that newly enveloped virions are incorporated into MPRci-containing vesicles in the trans Golgi network (3). These observations are compatible with the hypothesis that an interaction of viral glycoproteins with an MPR is important in viral entry. Such a mechanism may also influence the infection of cells by herpes simplex virus (HSV); HSV glycoprotein D (gD) acquires Man6P residues and binds to MPRs (4) . Binding of either VZV or HSV to an MPR, however, has yet to be demonstrated. Specific cell surface receptors are a critical factor in determining the range of cells that can be infected by a particular virus (5); therefore it is important to determine which receptors mediate infection of cells by VZV. Viral entry may involve more than a single receptor. Entry of HSV, for example, requires both initial attachment and subsequent internalization (6) (7) (8) . Different glycoproteins of the HSV envelope have been implicated in each of these steps. Adsorption of HSV is the responsibility of glycoprotein C (gC),
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. and mutant virions from which gC has been deleted are unable to bind to target cells (9, 10). In contrast, antibodies to gD do not inhibit the attachment of virions, but they do prevent the penetration of cells to which the virions have adsorbed (10). If gC and gD each interact with a different receptor, then the cellular protein responsible for adsorption would be different from that which mediates penetration. The cell surface molecules that interact either with gC or gD have not been identified, although gC of HSV-1 (9), like glycoproteins of other herpesviruses (11, 12), binds to heparin-like molecules. Genetic (6) and biochemical (7) studies of mutant CHO cell lines, defective in glycosaminoglycan (GAG) biosynthesis (13, 14) , also support the idea that a cell surface heparan sulfate proteoglycan (HSPG) is required for the attachment and subsequent infection of cells by HSV. It is plausible that the uptake of VZV, like that of HSV, involves more than a single step and more than one type of receptor. The current experiments were undertaken to test the hypotheses that adsorption of VZV is mediated by HSPG and that a receptor for which Man6P is a ligand plays a subsequent role in viral entry.
MATERIALS AND METHODS
Confluent monolayers of human embryonic lung fibroblasts (HELFs) and cell-free VZV were prepared as described (2). To determine the stage of viral infection affected by Man6P, HELF monolayers were exposed to cell-free VZV [>25 plaqueforming units (pfu)/ml]. Man6P (20 mM final concentration) was added at various intervals following inoculation. Cultures were then incubated for 3 or 4 days, after which plaques were counted. To analyze the effect of phosphorylated monosaccharides on the expression of gpl on the surfaces of infected cells, HELF monolayers were infected with -50 pfu of cell-free VZV in medium containing Man6P (10-20 mM) or glucose 1-phosphate (GlclP; 10-20 mM). Neither monosaccharide was added to controls. HELFs were cultured for 3 or 4 days and VZV gpl was quantified by RIA. For this assay, infected cells were exposed to a murine monoclonal antibody to VZV gpl for 30 min. After being washed, the cells were incubated with rabbit anti-mouse antibodies and then with 125I-labeled protein A. The cells were washed and solubilized, and their radioactivity was quantified by liquid scintillation. To determine the effect on infectivity of exposure of VZV to alkaline phosphatase, preparations of cellfree VZV were incubated in medium containing Escherichia coli alkaline phosphatase (0.3-1.0 unit/ml) for 2-60 min. Control preparations were similarly incubated but without the enzyme.
The method for ligand blot analysis using Heparin and chondroitin sulfate (Sigma) were utilized to study the effect of GAGs on the infection of HELFs by VZV. HELF monolayers were exposed to 25-50 pfu of cell-free VZV in medium that did or did not (controls) contain these molecules and incubated for 2 h at 37°C. After being washed, the cultures were maintained for 4 days, and plaques were counted. To study the effect of phosphorylated monosaccharides and GAGs on cell surface binding of VZV, HELF monolayers were exposed to 25-50 pfu of cell-free VZV at 4°C for 1 h in medium containing heparin (8 ,ug/ml), chondroitin sulfate (8 ,ug/ml), Man6P (20 mM), or GlclP (20 mM). The cells were washed with cold medium, and the amount of gpl on the cell surface was measured by RIA. VZV binding to affinity columns containing Sepharose CL-4B beads conjugated with heparin was assessed by adding cell-free VZV diluted with maintenance medium to the columns at room temperature. Control columns contained only supporting elements or unconjugated beads. The column flow-through and wash buffer were collected and added to HELF monolayers. Plaques were counted after 4 days. The effects of GAGs and phosphorylated monosaccharides on the attachment of VZV to the surfaces of HELF cells were evaluated by Southern analysis of dot blots (16). HELF monolayers were exposed to 25-50 pfu of cell-free VZV for 1 h. The cells were lysed in buffer (10.0 mM Tris HCl, pH 8.0/1.0 mM EDTA/250 mM NaCl/0.2% SDS/100 ,ug of proteinase K per ml) at 50°C for 4 h. DNA was extracted with phenol/ chloroform, precipitated with ethanol, air dried, and resuspended in buffer (10 mM Tris HCl, pH 7.4/1 mM EDTA). DNA probes prepared by random priming were labeled with Ag of denatured salmon sperm DNA per ml]. Hybridized blots were washed (twice in 2x SSC/0.1% SDS; once in 0.2x SSC/0.1% SDS). Blots were then exposed to film for 1 h at -70°C with an intensifying screen.
RESULTS

Man6P Antagonizes Infection of Cells by VZV and Acts at
an Early Stage in the Infective Process. To determine whether Man6P simply masks CPE or whether it actually prevents infection, we used an RIA to detect gpl on cell surfaces. Intact cells were exposed to anti-gpl and bound antibody was detected with 135I-labeled protein A. The amount of radioactivity (in cpm) bound to cells was proportional to the' amount of VZV in the inoculum; moreover, the cpm correlated well with estimates of infection obtained by quantifying CPE (Fig. 1 A  and B) . Expression of viral protein as a result of VZV infection can thus be quantified by RIA of gpl. Man6P was as effective in preventing expression of gpl as in suppressing CPE (Fig.   1 C) . These data confirm that Man6P protects cells from infection by VZV.
To determine when Man6P inhibits infection, Man6P (20 mM) was added at various times from 0 to 480 min following inoculation of HELF cells with VZV. Man6P afforded significant protection (P < 0.01) when added within 0-30 min of exposure to the virus but not when added after 120 min (Fig.  1D ). These observations indicate that Man6P blocks an early event in the infection of cells by VZV.
To determine whether VZV binds to MPRCi, VZV-related antigens from infected cells were separated by SDS/PAGE, blotted onto nitrocellulose, and probed with a biotinylated soluble form of the MPRCi. This assay has been used to demonstrate the binding of acid hydrolases to MPRCi (15).
Immunoblotting with antibodies to gpl confirmed that VZV antigens were present. The soluble MPRCi bound to several bands on the blots; however, there were no MPRci-labeled Alkaline phosphatase, units/ml FIG. 2. Dephosphorylation of cell-free VZV by exposure to alkaline phosphatase rapidly destroys infectivity. (A) Alkaline phosphatase inhibits infectivity of VZV within 2 min. Incubation of VZV in control medium at the same pH for the same period of time has no effect. (B) Effect of alkaline phosphatase on viral infectivity is concentration dependent.
bands in extracts from VZV-infected cells that were not also seen in extracts from uninfected cells (data not shown). As direct evidence for binding of VZV to the MPRCi was not obtained, we tested the role of phosphorylated glycoproteins of the viral envelope in infection. Cell-free VZV was treated with alkaline phosphatase, which has been shown to dephosphorylate Man6P residues of VZV glycoproteins and lysosomal enzymes (2, 17) . Alkaline phosphatase reduced the infectivity of VZV within 2 min (Fig. 2A) ; this effect was concentration dependent (Fig. 2B) . In contrast, incubation of the virus in control medium had no effect on infectivity. These observations are consistent with the idea that removal of Man6P from VZV envelope glycoproteins impairs infectivity.
Heparin Protects Cells from Infection by VZV. Heparin is known to inhibit the infection of cells by several viruses (7, 11, 18, 19) . The effect of heparin on the infection of HELFs by VZV was tested by adding heparin or, as a control, chondroitin sulfate (0.01-10 ,g/ml) to the medium at the same time as an inoculum containing cell-free VZV. Heparin (Fig. 3 A and B) but not chondroitin sulfate (Fig. 3B) was a potent and concentration-dependent antagonist of VZV infection; protection was a logarithmic function of the heparin concentration (r = 0.95; P < 0.001). The ED5o for heparin was 0.23 ,ug/ml (95% confidence limits = 0.16-0.26 ,ug/ml), and at 10 ,ug/ml, infectivity was almost eliminated (P < 0.001). In contrast, chondroitin sulfate did not affect VZV infectivity (r = 0.115).
Heparin (Fig. 4A) ; when added 90 min after inoculation, heparin was no longer effective (Fig. 4B) . Chondroitin sulfate did not protect HELFs from VZV at either time (Fig. 4 A and B) .
Heparin (10 ,uM) , which inhibits the sulfation of GAGs. Cell-free VZV (50 pfu) was then applied to the cultures for 60 min. Adhesion of VZV was measured by gpl RIA, and infectivity was assessed by plaque assay. Chlorate treatment reduced the adherence of VZV to HELFs by =60% (P < 0.001; n = 4) and inhibited infectivity much more strikingly ( Fig. 6B; (20 mM) , GlclP (20 mM), heparin (8 ,ug/ml), or chondroitin sulfate (Chond. S.; 8 ,ug/ml) and gpl binding was determined by RIA. Infectivity (CPE) was assessed in similarly treated cultures. For Man6P, the difference from control in CPE is significant (P < 0.001). For heparin, the differences from control in both CPE and bound gpl are significant (P < 0.001). None We found that heparin inhibited the infection of HELFs by VZV in a concentration-dependent manner, with a potency comparable to that of its ability to prevent infection of cells by HSV (6, 7). As with Man6P, the protective effect of heparin was exerted early in the infection process, consistent with the idea that heparin interferes with viral attachment to, or penetration of, target cells. In contrast to Man6P, heparin inhibited binding of VZV to cell surfaces at 4°C and its association with cells at 37°C; moreover, VZV bound to heparin. Antagonism by chlorate of proteoglycan sulfation inhibited both the adhesion of VZV to cell surfaces and infection, supporting the idea that VZV binds to cell surface HSPG. The specificity of heparin's effect suggests that the interaction of HSPG with VZV is a structural recognition event.
A heuristic model based on the current data that explains the penetration of target cells by VZV is as follows: VZV first attaches to cells by binding to an HSPG. This binding stabilizes the virions and enables them to interact with a cellular site that recognizes Man6P. This binding is probably weak, which is why prior HSPG stabilization is needed for the Man6P-dependent process to be effective. When presented by HSPG binding to the Man6P-dependent site, the latter receptor participates in mediating viral penetration. Evidence that the Man6P-dependent site is an MPR exists but remains indirect. The advantage of the two-step model for viral entry, involving sequential interactions with HSPG and a Man6P-dependent site, is that it can be tested. 
